期刊
DIGESTIVE AND LIVER DISEASE
卷 53, 期 4, 页码 456-460出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.dld.2020.07.013
关键词
Chronic hepatitis C; Direct acting antivirals; Ageing; Comorbidities
The study found that the population of CHC patients receiving DAAs is getting older and with more comorbidities, but this did not affect the sustained virological response rates.
Background and aims: Direct acting antiviral agents (DAAs) have revolutionized the landscape of chronic hepatitis C (CHC) enabling treatment of all those infected. It remains to be determined how the characteristics of those receiving treatment are changing. Materials and methods: We retrospectively analysed all the patients with CHC who received treatment with DAAs in a large referral centre since 01/01/2015. We stratified their demographic, clinical and virological characteristics at baseline and the sustained virological response (SVR) rates according to the year of treatment. Results: In the study were included 2565 patients. During the study period, the yearly proportion of men and cirrhotic patients decreased ( p < 0.001) whereas mean age increased from 59.8 to 62.2 years old ( p = 0.04). An increasing trend was observed in the foreign-born patients from 4.3% to 7.9%, without reaching statistical significance. The prevalence of comorbidities had also increased during the study period ( p < 0.001). Instead, the yearly number of experienced patients decreased significantly ( p < 0.001) as well as the mean MELD score of cirrhotic patients from 9 to 7.6 ( p < 0.001). SVR rates increased significantly, from 93.4% in 2015 to 97.1% in 2018 ( P < 0.05). Conclusions: The population of patients with CHC receiving DAAs is becoming older and with more comorbidities. Nevertheless, this did not impact SVR rates. Background and aims: Direct acting antiviral agents (DAAs) have revolutionized the landscape of chronic hepatitis C (CHC) enabling treatment of all those infected. It remains to be determined how the charac-teristics of those receiving treatment are changing. Materials and methods: We retrospectively analysed all the patients with CHC who received treatment with DAAs in a large referral centre since 01/01/2015. We stratified their demographic, clinical and viro-logical characteristics at baseline and the sustained virological response (SVR) rates according to the year of treatment. Results: In the study were included 2565 patients. During the study period, the yearly proportion of men and cirrhotic patients decreased ( p < 0.001) whereas mean age increased from 59.8 to 62.2 years old ( p = 0.04). An increasing trend was observed in the foreign-born patients from 4.3% to 7.9%, without reaching statistical significance. The prevalence of comorbidities had also increased during the study pe-riod ( p < 0.001). Instead, the yearly number of experienced patients decreased significantly ( p < 0.001) as well as the mean MELD score of cirrhotic patients from 9 to 7.6 ( p < 0.001). SVR rates increased signifi-cantly, from 93.4% in 2015 to 97.1% in 2018 ( P < 0.05). Conclusions: The population of patients with CHC receiving DAAs is becoming older and with more co-morbidities. Nevertheless, this did not impact SVR rates. (c) 2020 Published by Elsevier Ltd on behalf of Editrice Gastroenterologica Italiana S.r.l.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据